Fujifilm Holdings Corp. (OTCMKTS:FUJIY) Short Interest Update

Fujifilm Holdings Corp. (OTCMKTS:FUJIY) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 36,976 shares, a decrease of 60.0% from the August 31st total of 92,358 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 324,199 shares, the days-to-cover ratio is presently 0.1 days.

Fujifilm Price Performance

Shares of FUJIY traded down $0.16 during trading hours on Tuesday, reaching $10.50. 11,448 shares of the company’s stock traded hands, compared to its average volume of 321,680. The stock has a market cap of $26.12 billion, a PE ratio of 8.27, a price-to-earnings-growth ratio of 1.31 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.84 and a debt-to-equity ratio of 0.17. The firm’s 50 day simple moving average is $10.68 and its 200-day simple moving average is $10.30. Fujifilm has a 12 month low of $8.93 and a 12 month high of $12.99.

Fujifilm (OTCMKTS:FUJIY) last issued its quarterly earnings data on Thursday, August 6th. The technology company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.06). The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Fujifilm had a return on equity of 6.91% and a net margin of 7.61%.Fujifilm has set its FY 2026 guidance at 0.735-0.735 EPS. Equities analysts expect that Fujifilm will post 0.75 EPS for the current year.

Fujifilm Company Profile

Fujifilm Holdings Corporation, through its subsidiaries, develops and markets imaging, healthcare, business, and advanced technology products and services. The company traces its origins to Fuji Photo Film Co, Ltd., established in Japan in 1934 to manufacture photographic film. Over time, Fujifilm diversified beyond photographic materials as demand for traditional film declined.

Its healthcare activities include medical imaging systems, endoscopy equipment, in-vitro diagnostics, biopharmaceutical contract development and manufacturing, and life sciences products.